This tablet is a combined preparation comprising four API ingredients, namely, nimesulide, phenylephrine, cetirizine, and caffeine. The manufacturing of the fixed-dose combination requires careful consideration of compatibility of the ingredients, weighing accuracy, blend uniformity, compression parameters, and stability of the final dosage form.
Nimesulide 100MG + phenylephrine 10MG + Ceterizine 5MG + caffeine 30MG The listed formulation has the active ingredients added at different concentrations, therefore formulation development needs to guarantee homogeneity across the entire blend with respect to the standards defined in the specifications.
Appropriate pharmaceutical excipients may be added in accordance with the final formulation. Suitable excipients may include diluents, binders, disintegrants, lubricants, glidants, stabilizers and other adjuvant.
Preformulation studies on tablets might include particle size, bulk density, flowability, moisture content, compressibility, solubility and compatibility with the proposed excipient system. These studies are performed to decide the optimum technology for the manufacturing of finished tablets.
NIMESULIDE 100MG + PHENYLEPHRINE 10MG + CETIRIZINE 5MG + CAFFEINE 30MG TABLETS The physicochemical properties of the API can vary from one to the other. They may vary, for example, in particle size, density, flowability or concentration, and these variations could potentially affect blend uniformity.
So Nimesulide is the maximum amount claimed and the Cetirizine has been added in a much lower strength. These variations make the controlled blending crucial. Miniscule quantities are to be premixed with a portion of the excipient mixture prior to being divided into the large dose.
Particle-sievmg or milling or other particle siHing for particle-size-control can be evaluated dur- ing formulation development to optimize powder proper- ties. The goal is to produce a well-flowing blend with low seg- regation potential.
Excipient compatibility studies can be conducted to determine the physical and chemical interactions that occur between the active ingredients and the other formulation components. These tests can include appearance, moisture interaction, chemical stability and other parameters.
The sequence in which ingredients are added and mixing parameters are determined at development. Mixing time, equipment load and processing conditions may affect blend uniformity and all need appropriate control.
Sample of bulk blend may be representative for uniformity before compression.
Manufacture The processing of each batch begins with the receipt, identification, sampling, testing, and approval of all active ingredients and excipients. The medicines are dispensed accurately according to the approved master manufacturing formula using approved weighing equipments.
Based upon physical characteristics of the formulation, you could choose direct compression, dry granulation or other acceptable tablet processing. You may need to consider a process that will achieve desirable powder flow, good tabletability and uniform distribution of all active ingredients.
While blending, Nimesulide, Phenylephrine, Cetirizine and Caffeine are added sequentially in the order of manufacturing process. Controlled blending is carried out to ensure a homogenous blend of the batch.
If granulation is needed conditions are defined for granulation, drying, sizing and lubrication. The prepared blend or granules are then transferred to the compression phase.
Factors that can be controlled are tablet weight, thickness, hardness, compression force, speed of the machine and appearance of the tablet during tablet compression.
The formulation should have sufficient strength for handling and packaging but with suitable disintegration and dissolution characteristics as listed in the approved product specifications.
In-process testing at specified intervals can help to identify potential manufacturing variations and maintain batch-to-batch consistency.
4.2.2 Assessment of quality of finished product Quality control tests for the evaluation of the finished product are carried out by chemical and physical tests according to the pre-determined specification and the applicable pharmaceutical requirements.
Analytical testing may be performed for Nimesulide, Phenylephrine, Cetirizine and Caffeine (Identification, and Assay). Other quality parameters may be evaluated such as related substances, content uniformity of dosage units, dissolution, disintegration, average weight, hardness, friability, moisture content and physical characteristics.
The inclusion of four APIs in the same product means that any analytical procedures should be validated in the context of the identification and quantification of all four ingredients. Specific consideration may be required for the lower strength of Cetirizine in this regard.
Uniformity testing helps determine that individual tablets contain the correct amount of active ingredient. Representative sampling and reliable laboratory procedures will produce batch-quality results.
The physical properties of the tablets can be assessed including the colour, shape, dimensions, surface texture, and hardness and friability. The appearance can be checked against the specifications.
Finished-product testing is complemented by quality assurance procedures for raw-material qualification, equipment calibration, process validation, environmental monitoring, batch documentation, root cause analysis of deviations, change control, and final batch-release procedures.
These stability tests are performed to determine if NIMESULIDE 100MG + PHENYLEPHRINE 10MG + CETIRIZINE 5MG + CAFFEINE 30MG TABLETS preserve their specified chemical and physical quality during storage.
It can measure appearance, assay, parameters related to degradation, dissolution, disintegration, moisture content and other factors at scheduled time points.
The choice of packaging system must be based on the stability characteristics of the formulation and the level of protection needed. Appropriate pharmaceutical blister packs, strip packs and other container-closure systems may be used.
Packaging can be used to protect the tablets from moisture, light, mechanical damage, and other external influences which may have an effect on product quality. Compatibility of container-closure may also be assessed in the course of development.
Packaging Operations The packaging operations should ensure proper unit count, sealing, batch coding, labelling, secondary packaging and so on. Seals integrity is crucial for preserving the protective features of the packaging system selected.
Development stage stability data can be used to inform packing selections and establish shelf-life conditions in compliance with applicable regulations.
NIMESULIDE 100MG + PHENYLEPHRINE 10MG + CETIRIZINE 5MG + CAFFEINE 30MG TABLETS may be included in a balanced broad-line pharmaceutical product mix of combination tablets, capsules, syrups, suspensions, drops, creams, and the like. NIMESULIDE 100MG + PHENYLEPHRINE 10MG + CETIRIZINE 5MG + CAFFEINE 30MG TABLETS necessitates rigorous control starting from the purchase of raw materials to the release of finished products.
A professional manufacturing environment manages formulation-development teams, manufacturing staff, quality-control labs, quality-assurance teams, packaging experts, and regulatory teams. Standardized processes and specific criteria ensure consistency between production runs.
The multi-component dosage forms need to be controlled with more precision in areas such as dispensing accuracy, particle property, blending sequence, compression parameters, testing through analytical methods and monitoring of stability can be controlled to ensure the quality of the dosage form is maintained.
Some companies are launching an entire other PCD Pharma Franchise range, this medicine can be added to the systematic range. This is a fixed-dose drug that may be suitable with regards to formulation creation, efficient manufacturing, verification of analytical procedure, stability testing, packaging, and organization of data may ensure a successful range of pharmaceuticals.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech